Immunotherapy boost tested for tough throat cancers
NCT ID NCT03829722
Summary
This study tested whether adding the immunotherapy drug nivolumab to the standard treatment of radiation and chemotherapy could better control high-risk HPV-related throat cancer and keep it from returning. It involved 26 adults with advanced-stage cancer of the tonsils or base of the tongue. The main goal was to see if this combination improved two-year survival without the cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNX SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.